NK1 receptor antagonists clinical trials
A class of medicines: the studies that test any of its 8 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones. In MeSH: Neurokinin-1 Receptor Antagonists.
Get an email when these change. Save the nk1 receptor antagonists studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Medicines in this class
Studies that test each. A study of two counts under both, and once above.
Studies by the year they started
243 studies that test it; most in 2006 (22)
| Year | Studies |
|---|---|
| 2001 | 5 |
| 2002 | 5 |
| 2004 | 8 |
| 2005 | 12 |
| 2006 | 22 |
| 2007 | 15 |
| 2008 | 11 |
| 2009 | 15 |
| 2010 | 9 |
| 2011 | 15 |
| 2012 | 15 |
| 2013 | 7 |
| 2014 | 11 |
| 2015 | 11 |
| 2016 | 8 |
| 2017 | 9 |
| 2018 | 9 |
| 2019 | 8 |
| 2020 | 2 |
| 2021 | 13 |
| 2022 | 11 |
| 2023 | 5 |
| 2024 | 8 |
| 2025 | 3 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 112 · Other 132
GlaxoSmithKline (38) · Merck Sharp & Dohme LLC (28) · Bayer (21) · Vyne Therapeutics Inc. (11) · Sun Yat-sen University (6) · Tesaro, Inc. (5) · University of Pennsylvania (4) · Duke University (3)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing one of them · 244
- Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study ParticipantsRecruitingPhase 1BayerNCT07762287Written as Elinzanetant (BAY 3427080) treatment A
- Aprepitant for the Treatment of CLIFAHDDRecruitingEarly Phase 1The University of Texas Health Science Center at San AntonioNCT07845825Written as Aprepitant Powder for Oral Suspension
- Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and MetoclopramideNot yet recruitingPhase 4Montefiore Medical CenterNCT06740812Written as Fosaprepitant for Injection
- Aprepitant to Improve Same Day Discharge for TKANot yet recruitingPhase 4Endeavor HealthNCT07639723Written as Aprepitant Injection
- Antiemetic Fosaprepitant To Remedy Nausea and VomitingRecruitingPhase 2/3Montefiore Medical CenterNCT06382012Written as Fosaprepitant 150 mg
- Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis SurgeryRecruitingPhase 2IWK Health CentreNCT06357234Written as Aprepitant
- Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic SurgeryNot yet recruitingPhase 4Sir Mortimer B. Davis - Jewish General HospitalNCT07371728Written as Aprepitant
- Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer PatientsNot yet recruitingPhase 1Rabin Medical CenterNCT06931119Written as EMEND® (EE mend) (aprepitant) capsules (80mg +125mg) Marketing Authorization Holder and Importer: Merck Sharp & Dohme (Israel-1996) Company Ltd.
- Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV PreventionEnrolling by invitationNot applicableSamsung Medical CenterNCT05773950Written as fosaprepitant
- Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and VomitingNot yet recruitingPhase 3CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT06543966Written as Aprepitant Injection
- Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCCNot yet recruitingPhase 3Guangxi Medical UniversityNCT05711823Written as Aprepitant in combination with granisetron and dexamethasone
- Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast CancerNot yet recruitingPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05841849Written as Aprepitant
- A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06780085Written as Neurokinin-1 receptor antagonist
- Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical PatientsCompletedPhase 3Centre hospitalier de l'Université de Montréal (CHUM)NCT07248280Written as Aprepitant 40mg
- A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerActive, not recruitingPhase 3BayerNCT05587296Written as Elinzanetant (BAY3427080)
- Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated DataCompletedPhase 3Jennifer Holder-MurrayNCT04606264Written as Aprepitant
- A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the MenopauseCompletedPhase 3BayerNCT05042362Written as Elinzanetant (BAY3427080)
- A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)CompletedPhase 3BayerNCT05099159Written as Elinzanetant (BAY3427080)
- Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor PatientsCompletedPhase 3Sichuan Cancer Hospital and Research InstituteNCT06007586Written as Aprepitant Injection
- Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative NeoplasmsCompletedPhase 3University Hospital, BrestNCT03808805Written as Aprepitant 80 mg
See all 244 studies that test one of the nk1 receptor antagonists →
Codes
What other systems call NK1 receptor antagonists · ClinicalTrials.gg INT008974
- MeSH (NLM) D064729Neurokinin-1 Receptor AntagonistsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D064729 | Neurokinin-1 Receptor Antagonists | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.